RxDoctor Payments Data

Evans Tran, PA

Physician Assistant · Los Alamitos, CANPI 1750632253

Payments from drug & device makers

$13,805in general payments, 2019–2025

Across 256 payments — averaging $53.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$7K
  • Axonics, Inc.$2K
  • Dendreon Pharmaceuticals LLC$714
  • Medtronic$685
  • Astellas Pharma US Inc$555
  • Antares Pharma, Inc.$493
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$1881%
  • Speaking & faculty fees$3,62526%
  • Travel & lodging$2,22216%
  • Food & beverage$7,31153%
  • Education$4603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,805 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$11,464
Medicare patients
64
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron57$56,042
MyrbetriqMirabegron51$40,471
Methenamine Hippurate19$2,881
Tamsulosin Hcl154$2,461
Estradiol44$2,039
Solifenacin Succinate65$1,864
NitrofurantoinNitrofurantoin Macrocrystal28$822
Oxybutynin Chloride ErOxybutynin Chloride30$630
Finasteride39$522
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst40$352
Testosterone Cypionate15$321
Alfuzosin Hcl ErAlfuzosin Hcl16$267
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim47$161
Ciprofloxacin Hcl23$131
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$215$56,04257 claims
Astellas Pharma US IncMyrbetriq$555$40,47151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →